ECSP055781A - Composiciones oftálmicas para el tratamiento de la hipertensión ocular - Google Patents

Composiciones oftálmicas para el tratamiento de la hipertensión ocular

Info

Publication number
ECSP055781A
ECSP055781A EC2005005781A ECSP055781A ECSP055781A EC SP055781 A ECSP055781 A EC SP055781A EC 2005005781 A EC2005005781 A EC 2005005781A EC SP055781 A ECSP055781 A EC SP055781A EC SP055781 A ECSP055781 A EC SP055781A
Authority
EC
Ecuador
Prior art keywords
treatment
ophthalm
compositions
eye
eye hypertension
Prior art date
Application number
EC2005005781A
Other languages
English (en)
Inventor
James B Doherty
Meng-Hsin Chen
Luping Liu
Swaminathan R Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP055781A publication Critical patent/ECSP055781A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se relaciona con compuestos potentes bloqueadores del canal de potasio de Fórmula I o una formulación de ellos para el tratamiento del glaucoma y otras condiciones las cuales conducen a elevar la presión intraocular en el ojo de un paciente. Esta invención también se relaciona con el uso de tales compuestos para dar un efecto neuroprotector al ojo de especies mamíferas, particularmente humanos.
EC2005005781A 2002-11-08 2005-05-06 Composiciones oftálmicas para el tratamiento de la hipertensión ocular ECSP055781A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42480802P 2002-11-08 2002-11-08
US50009103P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
ECSP055781A true ECSP055781A (es) 2005-09-20

Family

ID=32314559

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005781A ECSP055781A (es) 2002-11-08 2005-05-06 Composiciones oftálmicas para el tratamiento de la hipertensión ocular

Country Status (22)

Country Link
US (2) US7196082B2 (es)
EP (1) EP1562909B1 (es)
JP (2) JP4456072B2 (es)
KR (1) KR20050072805A (es)
AR (1) AR041991A1 (es)
AU (2) AU2003286884A1 (es)
BR (1) BR0316040A (es)
CA (1) CA2505086C (es)
CL (1) CL2003002293A1 (es)
DO (1) DOP2003000747A (es)
EC (1) ECSP055781A (es)
HR (1) HRP20050409A2 (es)
IS (1) IS7822A (es)
MA (1) MA27497A1 (es)
MX (1) MXPA05004889A (es)
NO (1) NO20052751D0 (es)
NZ (1) NZ539593A (es)
PE (1) PE20040692A1 (es)
PL (1) PL377172A1 (es)
RU (1) RU2005117627A (es)
TW (1) TWI250873B (es)
WO (2) WO2004043932A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040028469A (ko) 2002-09-30 2004-04-03 엘지전자 주식회사 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004272546B2 (en) * 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
CA2574078A1 (en) * 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
SI1981851T1 (sl) * 2006-01-31 2012-05-31 Array Biopharma Inc Kinazni inhibitorji in postopki za njihovo uporabo
CA2644716A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
EP2352501B1 (en) * 2008-11-03 2014-01-01 ChemoCentryx, Inc. Compounds for use in the treatment of osteoporosis
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
BR112016025356B1 (pt) 2014-04-30 2023-04-18 The Trustees Of Columbia University In The City Of New York Compostos de 4-fenilpiperidinas substituídas, composições e seus usos
CN104211638A (zh) * 2014-08-13 2014-12-17 李增 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
ES2317964T5 (es) 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3208210B2 (ja) * 1993-03-17 2001-09-10 旭化成株式会社 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法
CA2164733A1 (en) 1993-06-08 1994-12-22 Nino Sorgente Methods and compositions for lowering intraocular pressure
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
EA005293B1 (ru) 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
EP1251862B1 (en) 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6956036B1 (en) * 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2001070701A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
WO2001072268A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie

Also Published As

Publication number Publication date
NO20052751L (no) 2005-06-07
US7547720B2 (en) 2009-06-16
PL377172A1 (pl) 2006-01-23
JP5061293B2 (ja) 2012-10-31
EP1562909B1 (en) 2012-06-27
HRP20050409A2 (en) 2006-02-28
IS7822A (is) 2005-04-25
AU2003286884A1 (en) 2004-06-03
JP4456072B2 (ja) 2010-04-28
JP2006508190A (ja) 2006-03-09
BR0316040A (pt) 2005-09-13
AU2003287506B2 (en) 2009-04-23
US20040097575A1 (en) 2004-05-20
CA2505086C (en) 2009-08-25
AR041991A1 (es) 2005-06-08
TW200501949A (en) 2005-01-16
MA27497A1 (fr) 2005-08-01
CL2003002293A1 (es) 2005-01-14
KR20050072805A (ko) 2005-07-12
TWI250873B (en) 2006-03-11
DOP2003000747A (es) 2004-05-31
EP1562909A1 (en) 2005-08-17
CA2505086A1 (en) 2004-05-27
WO2004043933A1 (en) 2004-05-27
AU2003287506B8 (en) 2009-05-28
AU2003287506A1 (en) 2004-06-03
RU2005117627A (ru) 2006-01-20
US20070129418A1 (en) 2007-06-07
US7196082B2 (en) 2007-03-27
MXPA05004889A (es) 2005-07-22
JP2010006825A (ja) 2010-01-14
WO2004043932A1 (en) 2004-05-27
PE20040692A1 (es) 2004-10-08
NO20052751D0 (no) 2005-06-07
NZ539593A (en) 2006-12-22

Similar Documents

Publication Publication Date Title
ECSP055781A (es) Composiciones oftálmicas para el tratamiento de la hipertensión ocular
MXPA03008401A (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
EP1646614A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
ES2182973T3 (es) Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
WO2002085248A3 (en) Prostanoids augment ocular drug penetration
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
ITRM20010755A1 (it) Uso del chinone q10 per il trattamento delle malattie oculari.
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
DK1110554T3 (da) Medicinal præparater til behandling af öjensygdomme
BRPI0414699A (pt) formulações de acetato de anecortave e acetonida de triancinolona para injeção
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
HK1038694A1 (zh) 治疗眼、耳、鼻病症的抗生素合成剂
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
AR018272A1 (es) Una composicion oftalmica para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesia de la corneadeteriorada y el uso del ingrediente activo de dicha composicion para la preparacion de dicha composicion oftalmica.
DE602006003438D1 (de) Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
ATE511506T1 (de) Thiopen-derivate als wirkstoffe gegen okulare hypotonie